Cryoablation

IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference

Retrieved on: 
Thursday, March 7, 2024

CAESAREA, Israel, March 7, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the Company's Chief Executive Officer, Eyal Shamir, will present at the 34th Annual Oppenheimer Healthcare MedTech & Services Conference on Tuesday, March 12, 2024, at 8:00am EST.

Key Points: 
  • CAESAREA, Israel, March 7, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the Company's Chief Executive Officer, Eyal Shamir, will present at the 34th Annual Oppenheimer Healthcare MedTech & Services Conference on Tuesday, March 12, 2024, at 8:00am EST.
  • Investors may view the presentation at the virtual conference through the following LINK live and for 180 days following conference.
  • Mr. Shamir will provide an update on IceCure's latest developments including the Company's ICE3 breast cancer trial with its pending De Novo Classification Request with the U.S. Food and Drug Administration ("FDA") for marketing clearance of ProSense® for the treatment of patients with early-stage, low-risk breast cancer as well as ProSense®'s increasing global commercial reach and the growing body of independent research on the efficacy of cryoablation.

IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation

Retrieved on: 
Tuesday, January 16, 2024

CAESAREA, Israel, Jan. 16, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it participated at the Indian Society of Vascular and Interventional Radiology (ISVIR) 24th Annual Conference in Jaipur, India that took place from January 11th-14th, 2024.

Key Points: 
  • IceCure, along with its in-country distributor, Novomed, exhibited and conducted hands-on ProSense® demonstrations and training.
  • In his presentation titled "Ablation for Bone and Soft Tissue Masses: How I Do It", ISVIR President Dr. Suyash Kulkarni, described the benefits of using a liquid nitrogen cryoablation system.
  • Dr. Kulkarni gave several specific examples of how his team performed cryoablation to successfully treat bone and soft tissue masses.
  • "At this year's ISVIR conference, more interventional radiologists evaluated the advantages of using cryoablation in their practices and hospitals."

Global Cardiac Ablation Devices Market Analysis and Forecasts, 2017-2022 and 2023-2027 with 2022 as the Base Year Featuring Arga Medtech, Boston Scientific, Abbott, Johnson & Johnson, and Medtronic - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 9, 2024

This study analyzes the global cardiac ablation device market, including the entire market landscape by end-users, application types, device types, and market share percentage by market players.

Key Points: 
  • This study analyzes the global cardiac ablation device market, including the entire market landscape by end-users, application types, device types, and market share percentage by market players.
  • The study provides specific market growth opportunities focusing on disruptive innovations, new unaddressed markets, increasing prevalence of cardiac arrhythmia, and others.
  • Rising incidents of cardiac arrhythmia and the increasing demand for minimally invasive procedures boost the cardiac ablation (CA) market growth.
  • With the lessening of pandemic restrictions from 2022, the worldwide backlog of CA procedures surged the CA device market growth.

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results

Retrieved on: 
Wednesday, January 10, 2024

Increased Revenues, System, and Probe Sales: Based on our expected preliminary unaudited 2023 results, ProSense® system and disposable probe sales increased by 26% globally over 2022.

Key Points: 
  • Increased Revenues, System, and Probe Sales: Based on our expected preliminary unaudited 2023 results, ProSense® system and disposable probe sales increased by 26% globally over 2022.
  • On a preliminary unaudited basis, as of December 31, 2023, we had cash and cash equivalents, including short-term deposits, of $11 million.
  • The above information reflects preliminary unaudited estimates with respect to certain results of IceCure for the full year ended December 31, 2023, based on currently available information.
  • Because the audit for 2023 is not yet complete, the Company's final results may vary from the preliminary estimates provided herein.

New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response

Retrieved on: 
Wednesday, January 3, 2024

The Piezo1 study involved performing cryoablation with ProSense® on tumor volumes of approximately 100 mm3 (diameter ~6 mm) using a mouse model.

Key Points: 
  • The Piezo1 study involved performing cryoablation with ProSense® on tumor volumes of approximately 100 mm3 (diameter ~6 mm) using a mouse model.
  • The data demonstrates that cryoablation induces immune rejection by enhancing CD8+ T cell activation, a process dependent on T cell expression of Piezo1.
  • "These studies pave the way for analysis of immune response in the growing number of ProSense® cryoablation investigator-initiated trials in humans.
  • As always, we are very grateful to the doctors conducting these independent studies that explore and confirm ProSense®'s mechanism of action and its benefits for patients."

Medtronic creates history with FDA approval of its novel PulseSelect™ Pulsed Field Ablation System to treat atrial fibrillation

Retrieved on: 
Wednesday, December 13, 2023

DUBLIN, Dec. 13, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF). This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.

Key Points: 
  • This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.
  • "Launching the first FDA-approved PFA technology is not just a milestone; the PulseSelect PFA system is setting a new standard in safety for AF ablation with excellent efficacy and efficiency1.
  • The learning curve in using the catheter and system is short, and the catheter enables the operator to deliver fast and controlled pulsed field energy for AF ablation."
  • The PulseSelect PFA system also includes the following:
    Designed as a plug-and-play system, PulseSelect can be used with any mapping system or with just fluoroscopy2.

Study Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients"

Retrieved on: 
Wednesday, December 13, 2023

A total of 32 early-stage breast cancer patients with a median age of 70 (range of 50-91) were treated with cryoablation.

Key Points: 
  • A total of 32 early-stage breast cancer patients with a median age of 70 (range of 50-91) were treated with cryoablation.
  • Six of the 32 patients (18.5%) received adjuvant radiation, and 31 of 32 patients (97%) received adjuvant endocrine therapy.
  • The mean follow-up was 15 months, with 20 patients (62.5%) completing two years, and 12 patients (37.5%) completing more than three years.
  • Stated study co-author, Dr. Rakhshanda Layeequr Rahman
    "This independent study is quite compelling in that it goes beyond providing data.

IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights

Retrieved on: 
Wednesday, November 15, 2023

Gross profit was $0.73 million for the nine months ended September 30, 2023, compared to $0.98 million for the nine months ended September 30, 2022.

Key Points: 
  • Gross profit was $0.73 million for the nine months ended September 30, 2023, compared to $0.98 million for the nine months ended September 30, 2022.
  • Gross margin was 37% for the nine months ended September 30, 2023, compared to 46% for the nine months ended September 30, 2022.
  • Research and development expenses for the nine months ended September 30, 2023, were $6.39 million compared to $6.89 million for the nine months ended September 30, 2022.
  • Total operating expenses for the nine months ended September 30, 2023, were $12.89 million, compared to $13.79 million for the nine months ended September 30, 2022.

Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's ProSense® Cryoablation System

Retrieved on: 
Monday, November 6, 2023

In addition to the 12 studies already published in peer reviewed journals and presented in scientific conferences, two IceCure studies, ICE3 and ICESECRET, and 17 independent, non-sponsored studies are ongoing.

Key Points: 
  • In addition to the 12 studies already published in peer reviewed journals and presented in scientific conferences, two IceCure studies, ICE3 and ICESECRET, and 17 independent, non-sponsored studies are ongoing.
  • There are 13 published and ongoing studies for breast cancer.
  • The remaining studies are focused on fibroadenomas, endometriosis, and malignant or benign tumors of the lung, kidney, and musculoskeletal system.
  • Interim results show a 96.91% recurrence free rate, 100% safety, and 100% doctor and patient satisfaction with cosmetic results.

IceCure's ICE3 Trial Results Demonstrating 96.91% Recurrence Free Rate Featured in a Presentation at BISICON 2023 in India

Retrieved on: 
Monday, October 30, 2023

ProSense® was featured at Novomed's booth where doctors had the opportunity to get hands-on experience with the cryoablation system.

Key Points: 
  • ProSense® was featured at Novomed's booth where doctors had the opportunity to get hands-on experience with the cryoablation system.
  • ProSense® was installed and inaugurated at Kovai Medical Center and Hospital in May 2023 and in June 2023 the first breast cancer cryoablation procedure in India was successfully conducted.
  • Interim results, which were previously published, show a 96.91% recurrence free rate, 100% safety, and 100% doctor and patient satisfaction with cosmetic results.
  • "In conjunction with Novomed, we are eager to have ProSense® rolled out to more hospitals in India.